Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
暂无分享,去创建一个
Emily C. O'Brien | D. Singer | L. Allen | M. Ezekowitz | P. Kowey | J. Piccini | K. Mahaffey | E. Peterson | G. Fonarow | E. O'Brien | L. Thomas | Dajuanicia Simon | Paul Chang | Dajuanicia N Simon
[1] W. Nelson,et al. Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients , 2013, Current medical research and opinion.
[2] Paul J. Wang,et al. Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study. , 2013, American heart journal.
[3] T. Gomes,et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. , 2012, Archives of internal medicine.
[4] J. Spertus,et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians , 2012, Journal of multidisciplinary healthcare.
[5] G. Lip,et al. Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.
[6] A. Amin,et al. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. , 2012, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[7] B. Gersh,et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. , 2011, American heart journal.
[8] D. Singer,et al. Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation , 2010, Circulation. Cardiovascular quality and outcomes.
[9] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[10] J. Plumb,et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? , 2008, Journal of thrombosis and haemostasis : JTH.
[11] Susan Regan,et al. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.
[12] M. Rosenqvist,et al. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). , 2006, European heart journal.
[13] Colin Simpson,et al. Evidence for Age and Sex Differences in the Secondary Prevention of Stroke in Scottish Primary Care , 2005, Stroke.
[14] M. Ezekowitz,et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. , 2003, Clinical therapeutics.
[15] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[16] W. J. Hamilton,et al. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.
[17] S. Connolly,et al. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. , 1991, Circulation.
[18] P. Wolf,et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.
[19] Lippincott Williams Wilkins,et al. Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.
[20] K Y Liang,et al. Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.